This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.
Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $76.50 in the latest trading session, marking a +0.9% move from the prior day.
EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $83.39, marking a +1.81% move from the previous day.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $81.91, marking a +1.5% move from the previous day.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $76.70 in the latest trading session, marking a -1.92% move from the prior day.
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
by Zacks Equity Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $66.90, marking a -0.09% move from the previous day.
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why
by Zacks Equity Research
Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $55.68, marking a +0.27% move from the previous day.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q1 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate CTX001.
M&As in Spotlight With GSK Announcement: 3 Biotechs in Focus
by Zacks Equity Research
We discuss a few companies like uniQure (QURE), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY) with solid product portfolios and deep pipelines, which make them attractive candidates for a potential takeover in 2022.
Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?
by Zacks Equity Research
In 2022, Vertex (VRTX) expects continued revenue growth as there are more than 25,000 patients who are addressable with Vertex's CF therapies.
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
by Zacks Equity Research
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?